Hjem › Atopisk dermatitt (eksem) › Arkansas
Kliniske studier for Atopisk dermatitt (eksem) i Arkansas
8 studier for Atopisk dermatitt (eksem) søker deltakere på steder i Arkansas.
Byer i Arkansas
Offisiell studietekst (engelsk)
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Fort Smith
RekruttererFase 2
Alder 18 til 100 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Hot Springs
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07298395A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Arkansas Research Trials, North Little Rock
RekruttererFase 3
Alder 2 til 11 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Dermatology Trial Associates, Inc, Bryant
RekruttererFase 2
Alder 18 til 65 · Alle kjønn · Oppdatert 28. aug. 2026 · NCT07599813A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Applied Research Center and Wellness Clinic /ID# 268547, Little Rock
RekruttererFase 3
Alder 2 til 11 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT06461897A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, North Little Rock
RekruttererFase 3
6 Months – 11 Years · Alle kjønn · Oppdatert 7. jul. 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Clinical Trials Institute - Northwest Arkansas /ID# 267290, Fayetteville
RekruttererFase 3
Alder 18 til 63 · Alle kjønn · Oppdatert 6. jul. 2026 · NCT06389136A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
- Arkansas Research Trials, North Little Rock
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 19. sep. 2025 · NCT06055361Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.